


WHAT IS CLAIMED IS:

1. A compound having the structure:



wherein:

R₁ and R₃ are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF₃, and OCH₃;

R₂ is selected from the group consisting of hydrogen, halogen, OH, OCH₃, OCH₂COOH, C(O)-aryl, NCS, NH₂, N₃, NHR₈, NHCH₂COOH, NHCOR₁₃, NHCONHR₁₃, NHCOSR₁₃;


R₄ and R₅ are each independently selected from the group consisting of hydrogen, OH, and halogen;

R₆ and R₇ are each independently selected from the group consisting of hydrogen and halogen;

R₈ is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH₃, and CF₃;

R₁₃ is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH₃, CF₃, and -CH₂R', wherein R' is halogen; or

wherein R₁ and R₂ taken together, R₂ and R₃ taken together, or R₄ and R₅ taken together form a group having the structure:



wherein each R_{14} is independently selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, $-C(O)R_{11}$, $-C(O)SR_{11}$, and




R_{12} , wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen and lower alkyl of from 1 to about 8 carbons;

with the proviso that 1) no more than one of R_1 , R_2 , and R_3 is OCH_3 or hydrogen, 2) when R_4 and R_5 are OH and R_2 is hydrogen, then R_1 and R_3 are not both CF_3 , 3) when R_4 and R_5 are OH and R_2 is hydrogen, OH, halogen, OCH_3 , or NH_2 , then R_1 and R_3 are not both halogen, and 3) when R_4 and R_5 are OH and R_2 is NH_2 or $NHCOR_{13}$, then R_1 and R_3 are not halogen or hydrogen;

or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1, wherein both R_4 and R_5 are OH.
3. The compound of Claim 1, wherein R_5 is OH and R_4 is hydrogen or halogen.
4. The compound of Claim 1, wherein R_6 and R_7 are each halogen.
5. The compound of Claim 1, wherein R_6 and R_7 are each hydrogen.
6. The compound of Claim 1, wherein R_2 is OCH_3 , NH_2 , or $NHCOR_{13}$.
7. The compound of Claim 1, wherein R_1 and R_3 are halogen.
8. The compound of Claim 1, wherein R_1 is halogen, R_2 is OCH_3 or NH_2 , and R_3 is hydrogen.
9. The compound of Claim 1, wherein R_5 is OH, R_4 is hydrogen or halogen, R_2 is OCH_3 , NH_2 , or $NHCOR_{13}$, and R_1 and R_3 are halogen.

10. The compound of Claim 1, having the structure:



wherein:

R₁ and R₃ are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF₃, and OCH₃;

R₂ is selected from the group consisting of hydrogen, halogen, OH, OCH₃, OCH₂COOH, C(O)-aryl, NCS, NH₂, N₃, NHR₈, NHCH₂COOH, NHCOR₁₃, NHCONHR₁₃, NH COSR₁₃;

R₄ and R₅ are each independently selected from the group consisting of hydrogen, OH, and halogen;

R₆ and R₇ are each independently selected from the group consisting of hydrogen and halogen;

R₈ is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH₃, and CF₃; and


R₁₃ is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH₃, CF₃, and -CH₂R', wherein R' is halogen;

wherein no more than one of R₁, R₂, and R₃ is OCH₃ or hydrogen and one, but not both, of R₄ and R₅ is OH;

or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 10, wherein R₄ is OH and R₅ is hydrogen or halogen.

12. The compound of Claim 10, wherein R₅ is OH and R₄ is hydrogen or halogen.
13. The compound of Claim 10, wherein R₆ and R₇ are each halogen.
14. The compound of Claim 10, wherein R₆ and R₇ are each hydrogen.
15. The compound of Claim 10, wherein R₂ is OCH₃, NH₂, or NHCOR₁₃.
16. The compound of Claim 10, wherein R₁ and R₃ are halogen.
17. The compound of Claim 10, wherein R₁ is halogen, R₂ is OCH₃ or NH₂, and R₃ is hydrogen.
18. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and at least one compound having the structure:



wherein:

R₁ and R₃ are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF₃, and OCH₃;

R₂ is selected from the group consisting of hydrogen, halogen, OH, OCH₃, OCH₂COOH, C(O)-aryl, NCS, NH₂, N₃, NHR₈, NHCH₂COOH, NHCOR₁₃, NHCONHR₁₃, NHCOSR₁₃;


R_4 and R_5 are each independently selected from the group consisting of hydrogen, OH, and halogen;

R_6 and R_7 are each independently selected from the group consisting of hydrogen and halogen;


R_8 is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH_3 , and CF_3 ;

R_{13} is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH_3 , CF_3 , and $-CH_2R'$, wherein R' is halogen; or

wherein R_1 and R_2 taken together, R_2 and R_3 taken together, or R_4 and R_5 taken together form a group having the structure:



wherein each R_{14} is independently selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, $-C(O)R_{11}$, $-C(O)SR_{11}$, and



, wherein R_{11} and R_{12} are each independently selected from the group consisting of hydrogen and lower alkyl of from 1 to about 8 carbons;

with the proviso that 1) no more than one of R_1 , R_2 , and R_3 is OCH_3 or hydrogen, 2) when R_4 and R_5 are OH and R_2 is hydrogen, then R_1 and R_3 are not both CF_3 , 3) when R_4 and R_5 are OH and R_2 is hydrogen, OH, halogen, OCH_3 , or NH_2 , then R_1 and R_3 are not both halogen, and 3) when R_4 and R_5 are OH and R_2 is NH_2 or $NHCOR_{13}$, then R_1 and R_3 are not halogen or hydrogen;


or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of Claim 18, wherein both R_4 and R_5 are OH.

20. The pharmaceutical composition of Claim 18, wherein R_5 is OH and R_4 is hydrogen or halogen.

21. The pharmaceutical composition of Claim 18, wherein R_6 and R_7 are each halogen.

22. The pharmaceutical composition of Claim 18, wherein R₆ and R₇ are each hydrogen.
23. The pharmaceutical composition of Claim 18, wherein R₂ is OCH₃, NH₂, or NHCOR₁₃.
24. The pharmaceutical composition of Claim 18, wherein R₁ and R₃ are halogen.
25. The pharmaceutical composition of Claim 18, wherein R₁ is halogen, R₂ is OCH₃ or NH₂, and R₃ is hydrogen.
26. The pharmaceutical composition of Claim 18, wherein R₅ is OH, R₄ is hydrogen or halogen, R₂ is OCH₃, NH₂, or NHCOR₁₃, and R₁ and R₃ are halogen.
27. The pharmaceutical composition of Claim 18, wherein said compound has the structure:



wherein:

R₁ and R₃ are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF₃, and OCH₃;

R_2 is selected from the group consisting of hydrogen, halogen, OH, OCH_3 , OCH_2COOH , $C(O)-aryl$, NCS, NH_2 , N_3 , NHR_8 , $NHCH_2COOH$, $NHCOR_{13}$, $NHCONHR_{13}$, $NHCOSR_{13}$;

R_4 and R_5 are each independently selected from the group consisting of hydrogen, OH, and halogen;

R_6 and R_7 are each independently selected from the group consisting of hydrogen and halogen;

R_8 is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH_3 , and CF_3 ; and

R_{13} is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH_3 , CF_3 , and $-CH_2R'$, wherein R' is halogen;

wherein no more than one of R_1 , R_2 , and R_3 is OCH_3 or hydrogen and one, but not both, of R_4 and R_5 is OH;

or a pharmaceutically acceptable salt thereof.

28. The pharmaceutical composition of Claim 27, wherein R_4 is OH and R_5 is hydrogen or halogen.

29. The pharmaceutical composition of Claim 27, wherein R_5 is OH and R_4 is hydrogen or halogen.

30. The pharmaceutical composition of Claim 27, wherein R_6 and R_7 are each halogen.


31. The pharmaceutical composition of Claim 27, wherein R_6 and R_7 are each hydrogen.

32. The pharmaceutical composition of Claim 27, wherein R_2 is OCH_3 , NH_2 , or $NHCOR_{13}$.

33. The pharmaceutical composition of Claim 27, wherein R_1 and R_3 are halogen.

34. The pharmaceutical composition of Claim 27, wherein R₁ is halogen, R₂ is OCH₃ or NH₂, and R₃ is hydrogen.

35. A method of stimulating, regulating or modulating metabolism of fats in adipose tissue in animals, comprising administering an effective amount of at least one compound having the structure:



wherein:

R₁ and R₃ are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF₃, and OCH₃;

R₂ is selected from the group consisting of hydrogen, halogen, OH, OCH₃, OCH₂COOH, C(O)-aryl, NCS, NH₂, N₃, NHR₈, NHCH₂COOH, NHCOR₁₃, NHCONHR₁₃, NHCOSR₁₃;


R₄ and R₅ are each independently selected from the group consisting of hydrogen, OH, and halogen;

R₆ and R₇ are each independently selected from the group consisting of hydrogen and halogen;

R₈ is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH₃, and CF₃;

R₁₃ is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH₃, CF₃, and -CH₂R', wherein R' is halogen; or

wherein R₁ and R₂ taken together, R₂ and R₃ taken together, or R₄ and R₅ taken together form a group having the structure:



wherein each R₁₄ is independently selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, -C(O)R₁₁, -C(O)SR₁₁, and



R₁₂, wherein R₁₁ and R₁₂ are each independently selected from the group consisting of hydrogen and lower alkyl of from 1 to about 8 carbons;

with the proviso that 1) no more than one of R₁, R₂, and R₃ is OCH₃ or hydrogen, 2) when R₄ and R₅ are OH and R₂ is hydrogen, then R₁ and R₃ are not both CF₃, 3) when R₄ and R₅ are OH and R₂ is hydrogen, OH, halogen, OCH₃, or NH₂, then R₁ and R₃ are not both halogen, and 3) when R₄ and R₅ are OH and R₂ is NH₂ or NHCOR₁₃, then R₁ and R₃ are not halogen or hydrogen;

or a pharmaceutically acceptable salt thereof.

36. The method of Claim 35, wherein both R₄ and R₅ are OH.

37. The method of Claim 35, wherein R₅ is OH and R₄ is hydrogen or halogen.

38. The method of Claim 35, wherein R₆ and R₇ are each halogen.

39. The method of Claim 35, wherein R₆ and R₇ are each hydrogen.


40. The method of Claim 35, wherein R₂ is OCH₃, NH₂, or NHCOR₁₃.

41. The method of Claim 35, wherein R₁ and R₃ are halogen.

42. The method of Claim 35, wherein R₁ is halogen, R₂ is OCH₃ or NH₂, and R₃ is hydrogen.

43. The method of Claim 35, wherein R₅ is OH, R₄ is hydrogen or halogen, R₂ is OCH₃, NH₂, or NHCOR₁₃, and R₁ and R₃ are halogen.

44. The method of Claim 35, wherein the compound has the structure:



wherein:

R_1 and R_3 are independently selected from the group consisting of hydrogen, halogen, alkyl, aryl alkyl, CF_3 , and OCH_3 ;

R_2 is selected from the group consisting of hydrogen, halogen, OH, OCH_3 , OCH_2COOH , $C(O)$ -aryl, NCS, NH_2 , N_3 , NHR_8 , $NHCH_2COOH$, $NHCOR_{13}$, $NHCONHR_{13}$, $NHCOSR_{13}$;

R_4 and R_5 are each independently selected from the group consisting of hydrogen, OH, and halogen;

R_6 and R_7 are each independently selected from the group consisting of hydrogen and halogen;

R_8 is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, halogen, OCH_3 , and CF_3 ; and

R_{13} is selected from the group consisting of hydrogen, lower alkyl of from 1 to about 8 carbons, phenyl, halogen, OCH_3 , CF_3 , and $-CH_2R'$, wherein R' is halogen;

wherein no more than one of R_1 , R_2 , and R_3 is OCH_3 or hydrogen and one, but not both, of R_4 and R_5 is OH;

or a pharmaceutically acceptable salt thereof.

45. The method of Claim 44, wherein R_4 is OH and R_5 is hydrogen or halogen.

46. The method of Claim 44, wherein R_5 is OH and R_4 is hydrogen or halogen.

47. The method of Claim 44, wherein R₆ and R₇ are each halogen.
48. The method of Claim 44, wherein R₆ and R₇ are each hydrogen.
49. The method of Claim 44, wherein R₂ is OCH₃, NH₂, or NHCOR₁₃.
50. The method of Claim 44, wherein R₁ and R₃ are halogen.
51. The method of Claim 44, wherein R₁ is halogen, R₂ is OCH₃ or NH₂, and R₃ is hydrogen.
52. The method of Claim 35, wherein the compound is administered with at least one pharmaceutically acceptable carrier.